| 0.4264 -0.086 (-16.75%) | 09-15 00:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.47 | 1-year : | 5.34 |
| Resists | First : | 2.97 | Second : | 4.57 |
| Pivot price | 0.69  |
|||
| Supports | First : | 0.38 | Second : | 0.31 |
| MAs | MA(5) : | 0.42 | MA(20) : | 1.54 |
| MA(100) : | 5.58 |
MA(250) : | 8.41 |
|
| MACD | MACD : | -1.1  |
Signal : | -1.1 |
| %K %D | K(14,3) : | 1 | D(3) : | 1 |
| RSI | RSI(14): 19.9 | |||
| 52-week | High : | 17.09 | Low : | 0.38 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CLBS ] has closed above bottom band by 43.3%. Bollinger Bands are 2.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.65 - 0.65 | 0.65 - 0.66 |
| Low: | 0.38 - 0.38 | 0.38 - 0.38 |
| Close: | 0.42 - 0.43 | 0.43 - 0.43 |
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Thu, 15 Sep 2022
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics - GlobeNewswire
Wed, 14 Sep 2022
Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics - GlobeNewswire
Wed, 27 Apr 2022
Caladrius Biosciences and Cend Therapeutics Announce Definitive Merger Agreement - GlobeNewswire
Tue, 01 Jun 2021
Caladrius Biosciences Announces Participation in Upcoming Conferences in June 2021 - GlobeNewswire
Mon, 29 Mar 2021
Caladrius Biosciences Inc (NASDAQ:CLBS) Receives Orphan Drug Designation For Its CD34+ Cell Therapy Product ... - BP Journal
Thu, 11 Jun 2020
Type 1 diabetes trial reaches full enrollment - Sanford Health News
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 60 (M) |
| Shares Float | 59 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 18.5 (%) |
| Shares Short | 544 (K) |
| Shares Short P.Month | 564 (K) |
| EPS | -0.53 |
| EPS Est Next Qtrly | -0.77 |
| EPS Est This Year | -2.43 |
| EPS Est Next Year | -2.96 |
| Book Value (p.s.) | 1.67 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -16.8 % |
| Return on Equity (ttm) | -23.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -0.81 |
| PEG Ratio | -0.1 |
| Price to Book value | 0.25 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.29 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2016-07-27 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|